doctor Find a doctor
OR
Breadcrumbs that show current page

SAGE 547-302

TO EVALUATE OPEN-LABEL USE OF SAGE-547 (ALLOPREGNANOLONE) IN THE TREATMENT OF SUBJECTS WITH SUPER-REFRACTORY STATUS EPILEPTICUS

Supported by SAGE

Principal Investigator at BMC: Anna Cervantes-Arslanian, MD

Inclusion Criteria:

  1. Subjects who have:
    •    Failed to respond to the administration of at least one first-line agent (eg, benzodiazepine or other emergent initial AED treatment), according to the institution’s standard of care, and;
    •    Failed to respond to at least one second-line agent (eg, phenytoin, fosphenytoin, valproate, phenobarbital, levetiracetam, or other urgent control AEDs), according to the institution’s standard of care, and;
    •    Not previously been administered a third-line agent, but have been admitted to an ICU with the intent of administering at least one third-line agent for at least 24 hours; or who have previously failed one or more wean attempts from 3rd-line agents and are now on continuous intravenous infusions of one or more 3rd-line agents and in an EEG burst suppression pattern; or who have previously failed one or more wean attempts from third-line agents and are now either not on at least one continuous infusion of a third-line agent or are on one or more continuous infusions of third-line agents, but not in an EEG burst suppression pattern.

Exclusion Criteria: 

  1. Subjects who are pregnant;
  2. Subjects with a known allergy to progesterone or allopregnanolone or any excipients in SAGE-547;
  3. Subjects with SRSE due to anoxic/hypoxic encephalopathy;
  4. Subjects who have any of the following:
    a.    a GFR low enough to warrant dialysis but for whatever reason, dialysis that would adequately remove Captisol is not planned;
    b.    severe cardiogenic or vasodilatory shock requiring 2 or more pressors that is not related to third-line agent use;
    c.    fulminant hepatic failure;
    d.    no reasonable expectation of recovery (for instance, a likely outcome is persistent vegetative state) or life-expectancy, in the opinion of the investigator, of less than 30 days;
    e.    a do not resuscitate (DNR) order;
  5. Subjects who are being administered more than 3 third-line agents concomitantly or in whom the qualifying wean cannot be completed within 24 hours; or who are being administered a third-line agent for other indications such as raised intra-cranial pressure that would preclude weaning according to this protocol;
  6. Subjects with a living will that does not allow heroic measures;
  7. Subjects who have been exposed to an investigational medication or device within 30 days; the exception to this is that participation in the Established Status Epilepticus Treatment Trial or ESETT within 30 days of screening for Study 547-SSE-302 is allowed;
  8. Subjects who have been treated with study drug or randomized in this or any other trial employing SAGE-547 previously;
  9. Subjects for whom it is not medically feasible to be transferred to a geographically accessible participating clinical trial site for Study 547-SSE-301.
OR